Jpmorgan Chase & CO Pliant Therapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.23 Trillion
- Q4 2024
A detailed history of Jpmorgan Chase & CO transactions in Pliant Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 197,251 shares of PLRX stock, worth $648,955. This represents 0.0% of its overall portfolio holdings.
Number of Shares
197,251
Previous 49,212
300.82%
Holding current value
$648,955
Previous $551,000
371.32%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding PLRX
# of Institutions
175Shares Held
65.8MCall Options Held
230KPut Options Held
746K-
Deep Track Capital, LP Greenwich, CT5.97MShares$19.6 Million3.46% of portfolio
-
Black Rock Inc. New York, NY4.97MShares$16.4 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.63MShares$15.2 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.23MShares$10.6 Million0.0% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY3.2MShares$10.5 Million1.61% of portfolio
About PLIANT THERAPEUTICS, INC.
- Ticker PLRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,682,000
- Market Cap $160M
- Description
- Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a tri...